uBiome Receives Patent for Microbiome-Derived Diagnostics and Therapeutics for Immune-Microbial Dysfunction

SAN FRANCISCO, Dec. 14, 2018 /PRNewswire-PRWeb/ -- uBiome, the leader in microbial genomics, announced the issue of patent number 9,703,929 entitled "Method and System for Microbiome-Derived Diagnostics and Therapeutics" by the US Patent and Trademark Office on July 11, 2017 with a priority date of October 21, 2014. The patent is an invention by uBiome collaborators Dr. Zachary Apte, Dr. Daniel Almonacid, Dr. Jessica Richman, and Dr. Siavosh Rezvan Behbahani, and expands upon previously filed intellectual property.

The patented technology involves characterizing an immune-microbial dysfunction and generating a therapy model by analyzing biological samples from uBiome's proprietary database. The microbiome compositions obtained with these products are useful in assisting a health care provider with the diagnosis of immune-microbial dysfunctions such as irritable bowel syndrome (IBS), Crohn's disease, ulcerative colitis, and celiac disease, among others.

This issuance creates the possibility of designing a therapy based on the modification of the microbiota using prebiotics and probiotics. It also opens up the possibility of predicting the likelihood of occurrence of immune-microbial dysfunction in individuals.

"uBiome's goal is to advance the science of the microbiome, and this technology allows us to do just that," Jessica Richman, PhD, co-founder and CEO of uBiome, said. "Diagnostics and therapeutics are an exciting frontier for microbiome-derived analysis and we are pleased to have been granted this patent."

For more information about our science and patents, visit http://www.ubiome.com/science/#patents.
_____
About uBiome
Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencingtm with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.

uBiome's commercial products include SmartGuttm, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJanetm, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorertm, a health and wellness product to understand the role that food and lifestyle can play in wellness.

uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.

Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.

SOURCE uBiome